Tardive Dyskinesia Treatment Market 2028 By Disorder, Drug Class, End User and Geography | The Insight Partners

report image

Tardive Dyskinesia Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disorder (Bradykinesia, Hyperkinesia); Drug Class (Dopamine-Depleting Medications, VMAT2 Inhibitors, GABA Receptor Agonist Medications, Anticholinergic Medications Trihexyphenidyl); End User (Hospitals, Clinical, Others) and Geography

Report Code: TIPRE00021909 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming


Tardive Dyskinesia treatment is result of side effects of antipsychotic drugs. These types of drugs are used to treat mental disorders such as schizophrenia and others. Involuntary muscle movements are symptoms of Tardive Dyskinesia. The treatment of the disorder includes inhibiting the use of drugs causing and aggravating the disorder.


The Tardive Dyskinesia treatment market is driving due to the rise in population with neurological disorders . However, lack of diagnosis of Tardive Dyskinesia treatment are expected to hamper the growth of the global Tardive Dyskinesia treatment market.


The "Tardive Dyskinesia Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Tardive Dyskinesia Treatment market with detailed market segmentation by disorder and drug class and end user. The Tardive Dyskinesia Treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Tardive Dyskinesia Treatment market and offers key trends and opportunities in the market.


The Tardive Dyskinesia treatment market is segmented on the basis of disorder, drug class and end user. Based on disorder, the market is segmented as Bradykinesia, Hyperkinesia. On the basis of drug class, the market is categorized as Dopamine-Depleting Medications, VMAT2 Inhibitors, GABA Receptor Agonist Medications and Anticholinergic Medications Trihexyphenidyl. On the basis of end user, the market is categorized as Hospitals, Clinical and others


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Tardive Dyskinesia Treatment market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Tardive Dyskinesia Treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Tardive Dyskinesia Treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Tardive Dyskinesia Treatment market in these regions.

Get more information on this report :


The report covers key developments in the Tardive Dyskinesia Treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Tardive Dyskinesia Treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for Tardive Dyskinesia Treatment in the global market. Below mentioned is the list of few companies engaged in the Tardive Dyskinesia Treatment market.

The report also includes the profiles of key players in Tardive Dyskinesia Treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Teva Pharmaceutical Industries Ltd
  •   Neurocrine Biosciences, Inc
  •   Sun Pharmaceutical Industries Ltd
  •   SteriMax Inc.
  •   Adamas Pharmaceuticals, Inc
  •   Sanis
  •   AbbVie Inc.
  •   Mylan N.V,
  •   Reddy's Laboratories Ltd,
  •   Sun Pharmaceutical Industries Ltd

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Get more information on this report :

The List of Companies

1. Teva Pharmaceutical Industries Ltd
2. Neurocrine Biosciences, Inc
3. Sun Pharmaceutical Industries Ltd
4. SteriMax Inc.
5. Adamas Pharmaceuticals, Inc
6. Sanis
7. AbbVie Inc.
8. Mylan N.V,
9. Reddy’s Laboratories Ltd,
10. Sun Pharmaceutical Industries Ltd
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount